A nanocarrier drug delivery platform that provides a pharmaceutical composition configured for selective uptake by lymph nodes and dissemination throughout the lymphatic system such that administration of the composition provides therapeutic efficacy at lymph nodes both proximal and distal to the site of administration. A three-drug loaded version of the nanocarrier vehicle was successfully tested for safety and efficacy in two transgenic metastatic melanoma models.
Features & Benefits
Background of Invention
Metastatic melanoma has a high mortality rate due to lymphatic progression of the disease. Current treatment for late stage metastatic melanoma is surgery followed by radiation and intravenous chemotherapy; however, drawbacks for current chemotherapeutics lie in the fact that they develop resistance and do not achieve therapeutic concentrations in the lymphatic system.
Patent pending; available for exclusive licensing